In 2002 a large trial was halted early, the news went round the world as "hormone therapy causes breast cancer", and within months millions of women stopped treatment. Two decades of advice, training and fear followed from that moment. It is worth understanding properly, because much of what you will still be told — by relatives, by forums, sometimes by clinicians — dates from it.
Where we stand: Menova is an independent publication. We sell no hormones and take no payment for placement, we are not your doctor, and this is general education, not medical advice.
What the trial was
The Women's Health Initiative was a large randomised trial in the United States. Crucially, it was not designed to ask "does HRT help menopausal symptoms?" It was designed to ask whether hormone therapy prevented chronic disease — heart disease in particular — in older postmenopausal women.
That design decision explains almost everything that followed.
The participants were older than the women who typically start treatment. Average age at enrolment was around 63, and many were more than a decade past menopause. Someone starting at 63 is a different physiological proposition from someone starting at 50 with hot flashes.
It tested particular preparations. Oral conjugated equine estrogen, with or without a specific synthetic progestogen. Not patches, not gels, not the range of options now in use — and route turns out to matter, particularly for clot risk.
It had two arms. Combined therapy for women with a uterus, and estrogen-only for women who had had a hysterectomy. These produced different results, and the difference was largely lost in the reporting.
What it actually found
Stated carefully, because the details are the point.
The combined arm was stopped early in 2002. It found a small absolute increase in breast cancer diagnoses, alongside findings on clots and stroke — and also a reduction in fractures and colorectal cancer. The breast cancer finding is the one that travelled.
The estrogen-only arm ran longer and did not show an increase in breast cancer in the main findings. For many women this arm is the more relevant one, and almost nobody heard about it.
The absolute numbers were small. The headline figures were relative — a percentage increase on a small baseline — which sounds far larger than the actual change in the number of women affected. This is the single most consequential communication failure in the story, and it is why our guide to the actual breast cancer numbers exists.
It answered its own question. Hormone therapy was not shown to prevent heart disease in that older population, and it is not prescribed for disease prevention today. That conclusion has held.
What was wrong was the generalisation
The trial was large and carefully conducted. What went wrong was applying a result obtained in women around 63, on one oral preparation, taken for prevention, to a 50-year-old with hot flashes considering a patch for symptoms.
Those are different questions, and the answer to one was reported as the answer to all of them.
What happened next
Prescribing fell sharply and quickly. Several consequences followed that are still with you:
A generation went untreated, including women with severe symptoms and women with early menopause, for whom the calculation is different and stronger.
Menopause disappeared from training. If a treatment is considered dangerous, teaching about it shrinks. Much of the "my doctor didn't seem to know" experience women describe today traces back to this — see finding a clinician who knows menopause.
A vacuum opened, and it was filled commercially. Compounded "bioidentical" hormones, supplement protocols and hormone-testing panels grew in exactly the space that mainstream care vacated — see bioidentical hormones explained, compounded versus FDA-approved and estrogen dominance and hormone balancing.
The fear was inherited. Women now in their forties absorbed it from mothers who were told to stop overnight, often without an explanation.
What has changed since
Age and timing are now central. The trade-off looks different for a woman starting near the time of menopause than for one starting many years later — often described as the timing hypothesis. Guidance now treats age at initiation and time since menopause as central rather than incidental.
Route matters. Transdermal and oral routes behave differently, notably for clot risk, which was not something the trial could tell you — see HRT types and forms and HRT and blood clot risk.
Local vaginal estrogen is understood as a separate question. Low dose, acting locally, minimal absorption — and in November 2025 the FDA removed the long-standing boxed warning from low-dose vaginal estrogen products, a warning that had been carried over from systemic findings. See is vaginal estrogen safe and the 2025 FDA warning change.
Symptom relief is the recognised indication. Treatment is for symptoms, and for bone protection in specific situations — not for preventing chronic disease.
Early menopause is treated differently. Where ovarian function is lost well before the usual age, hormone therapy is generally recommended at least to the typical age of menopause, and the framing is replacement rather than addition — see early and surgical menopause and BRCA and risk-reducing surgery.
What has not changed
Being fair requires saying this too.
Combined therapy is associated with a small absolute increase in breast cancer risk that grows with duration and declines after stopping. That was true then and it is true now. It should be disclosed, and it is a legitimate thing to weigh — see HRT risks and benefits.
It is not prescribed to prevent disease.
Individual history still decides it. Previous breast cancer, clot history, migraine with aura, liver disease — these change the recommendation or the route.
Long-duration use remains less well characterised than short-term use, and honest guidance says so — see how long you can stay on HRT.
Anyone telling you the WHI was simply "debunked" is doing the same thing the 2002 headlines did, in the opposite direction.
What this means for you
If you were told to stop in 2002 or soon after, that advice reflected the understanding of the time. Whether it still applies to you is a current question with a current answer, and it is reasonable to reopen — see HRT in your 60s and beyond.
If your fear came from your mother's experience, it is worth separating the two: her situation, her age, her preparation, and what was known then.
If a clinician quotes the trial at you without mentioning age at initiation or route, that is a reasonable thing to ask about directly — see what to do if your doctor says no.
And whatever you conclude, the decision is still yours to weigh rather than one the evidence settles — see when you can't decide about HRT.
Our free printable visit prep sheet keeps the conversation to one page, and the free 2-minute Menova self-check organizes your symptom picture — no account, not a diagnosis, and your answers never leave your device.
This article is general education, not medical advice, and not a recommendation for or against hormone therapy. It is a summary of a large body of research and its interpretation, both of which continue to develop. Decisions belong with a licensed clinician who knows your history.
Sources: NHLBI — Women's Health Initiative, The Menopause Society, NICE NG23 — Menopause, and ACOG — The Menopause Years.